The Hyderabad-based Aurobindo Pharma is planning to treble its turnover in the next three-four years.
The company, which had posted a turnover of around Rs 996 crore last fiscal, is now eyeing sales in excess of Rs 3,000 crore.
"Our turnover should cross Rs 3000-4000 crore in the next two-three years. Later, we would buy a company manufacturing generic drugs or one that develops non-infringing processes. We are also open to picking up stakes in such companies instead of an outright buyout. This will be the next step in emerging as a global player in the bulk and generics segments," said Srinivas Lanka, director, Aurobindo Pharma.
Also Read
The company's turnover is expected to cross the Rs 1,000 crore mark this fiscal with exports accounting for Rs 550 crore.
Aurobindo has already submitted about 800 dossiers in 72 countries for formulations and has received 281 approvals so far.
"In many regulated markets, we would be looking at becoming the second or third supplier for the off patent drug," he said.
The company also plans to get listed internationally in the next 18 months, he added. Aurobindo has also set a target of Rs 1,000 crore for exports in three years.
"We will meet this target by directly exporting in some cases. In other cases, the company will enter into joint ventures abroad which will market these products," he said.
The company has designated three 'hubs' in order to regulate its export business for global generics. India will look after part of Asia and the Middle East, while China will look after supplies to far eastern countries. It 's outfit in Brazil will look after the Latin American markets.
The company, which is in the last stages of its restructuring, has set up two formulation units in India and one in Los Angeles in order to cater to the regulated markets.
Aurobindo has already invested Rs 188 crore in the process. It is also proposing to invest another Rs 50 crore by the second half of the next fiscal.
In the domestic market, the company is primarily a player in the manufacture of bulk drugs or active pharmaceutical ingredient with four per cent of its turnover from formulations.